USD 2.45
(6.99%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 | 87 Thousand USD | 0.0% |
2023 | 162 Thousand USD | -47.57% |
2022 | 309 Thousand USD | -83.2% |
2021 | 1.83 Million USD | 146.51% |
2020 | 746 Thousand USD | 6116.67% |
2019 | 12 Thousand USD | -93.18% |
2018 | 176 Thousand USD | -17.37% |
2017 | 213 Thousand USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | -100.0% |
2014 | 4000.00 USD | -99.41% |
2013 | 676 Thousand USD | -62.94% |
2012 | 1.82 Million USD | 11.36% |
2011 | 1.63 Million USD | 1389.09% |
2010 | 110 Thousand USD | 48.65% |
2009 | 74 Thousand USD | -64.93% |
2008 | 211 Thousand USD | -89.53% |
2007 | 2.01 Million USD | 702.79% |
2006 | 251 Thousand USD | -51.73% |
2005 | 520 Thousand USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 134 Thousand USD | 0.0% |
2024 Q3 | 160 Thousand USD | 0.0% |
2024 Q4 | 87 Thousand USD | 0.0% |
2024 FY | 87 Thousand USD | -46.3% |
2024 Q1 | 121 Thousand USD | 0.0% |
2023 FY | 162 Thousand USD | -47.57% |
2023 Q3 | 210 Thousand USD | -20.15% |
2023 Q2 | 263 Thousand USD | 1.15% |
2023 Q4 | 162 Thousand USD | -22.86% |
2023 Q1 | 260 Thousand USD | -15.86% |
2022 FY | 309 Thousand USD | -83.2% |
2022 Q4 | 309 Thousand USD | -14.64% |
2022 Q3 | 362 Thousand USD | -14.62% |
2022 Q2 | 424 Thousand USD | -10.17% |
2022 Q1 | 472 Thousand USD | -74.33% |
2021 Q3 | 1.78 Million USD | 0.11% |
2021 Q2 | 1.77 Million USD | 16.27% |
2021 FY | 1.83 Million USD | 146.51% |
2021 Q1 | 1.53 Million USD | 105.09% |
2021 Q4 | 1.83 Million USD | 3.26% |
2020 Q3 | 807 Thousand USD | -6.71% |
2020 FY | 746 Thousand USD | 6116.67% |
2020 Q1 | 933 Thousand USD | 7675.0% |
2020 Q4 | 746 Thousand USD | -7.56% |
2020 Q2 | 865 Thousand USD | -7.29% |
2019 Q3 | 14 Thousand USD | -83.91% |
2019 FY | 12 Thousand USD | -93.18% |
2019 Q1 | 133 Thousand USD | -24.43% |
2019 Q2 | 87 Thousand USD | -34.59% |
2019 Q4 | 12 Thousand USD | -14.29% |
2018 Q2 | 255 Thousand USD | -13.27% |
2018 FY | 176 Thousand USD | -17.37% |
2018 Q4 | 176 Thousand USD | -17.76% |
2018 Q3 | 214 Thousand USD | -16.08% |
2018 Q1 | 294 Thousand USD | 38.03% |
2017 FY | 213 Thousand USD | 0.0% |
2017 Q4 | 213 Thousand USD | 343.75% |
2017 Q3 | 48 Thousand USD | -4.0% |
2017 Q2 | 50 Thousand USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | -100.0% |
2015 Q1 | 1000.00 USD | -75.0% |
2015 Q4 | - USD | 0.0% |
2015 FY | - USD | -100.0% |
2014 Q2 | 519 Thousand USD | -25.43% |
2014 Q4 | 4000.00 USD | -66.67% |
2014 Q1 | 696 Thousand USD | 2.96% |
2014 Q3 | 12 Thousand USD | -97.69% |
2014 FY | 4000.00 USD | -99.41% |
2013 Q1 | 1.44 Million USD | -20.94% |
2013 Q4 | 676 Thousand USD | 59.43% |
2013 Q3 | 424 Thousand USD | -61.17% |
2013 Q2 | 1.09 Million USD | -24.27% |
2013 FY | 676 Thousand USD | -62.94% |
2012 Q1 | 2.1 Million USD | 28.51% |
2012 FY | 1.82 Million USD | 11.36% |
2012 Q4 | 1.82 Million USD | -20.35% |
2012 Q3 | 2.29 Million USD | 34.63% |
2012 Q2 | 1.7 Million USD | -19.19% |
2011 FY | 1.63 Million USD | 1389.09% |
2011 Q4 | 1.63 Million USD | -11.84% |
2011 Q3 | 1.85 Million USD | 14.83% |
2011 Q1 | 1.55 Million USD | 1317.27% |
2011 Q2 | 1.61 Million USD | 3.78% |
2010 Q2 | 107 Thousand USD | 64.62% |
2010 Q4 | 110 Thousand USD | -9.09% |
2010 Q3 | 121 Thousand USD | 13.08% |
2010 FY | 110 Thousand USD | 48.65% |
2010 Q1 | 65 Thousand USD | -12.16% |
2009 Q2 | 130 Thousand USD | -12.75% |
2009 Q4 | 74 Thousand USD | -33.33% |
2009 FY | 74 Thousand USD | -64.93% |
2009 Q1 | 149 Thousand USD | -29.38% |
2009 Q3 | 111 Thousand USD | -14.62% |
2008 Q1 | 1.65 Million USD | -17.92% |
2008 Q2 | 1.21 Million USD | -26.48% |
2008 Q3 | 761 Thousand USD | -37.42% |
2008 Q4 | 211 Thousand USD | -72.27% |
2008 FY | 211 Thousand USD | -89.53% |
2007 FY | 2.01 Million USD | 702.79% |
2007 Q3 | 2.45 Million USD | -13.96% |
2007 Q2 | 2.85 Million USD | 0.0% |
2007 Q4 | 2.01 Million USD | -17.89% |
2006 Q4 | 251 Thousand USD | 0.0% |
2006 FY | 251 Thousand USD | -51.73% |
2005 Q4 | 520 Thousand USD | 0.0% |
2005 FY | 520 Thousand USD | 0.0% |
2003 FY | - USD | 0.0% |
2002 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.982% |
Embecta Corp. | 1.62 Billion USD | 99.995% |
ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.972% |
Dynavax Technologies Corporation | 252.41 Million USD | 99.966% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 99.983% |
Pacira BioSciences, Inc. | 513.79 Million USD | 99.983% |
PainReform Ltd. | 30 Thousand USD | -190.0% |
Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.904% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 83.86% |
SCYNEXIS, Inc. | 12.15 Million USD | 99.284% |
China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | 25.723% |
Cosmos Health Inc. | 3.03 Million USD | 97.134% |
Journey Medical Corporation | 14.62 Million USD | 99.405% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 83.86% |
Safety Shot Inc | 304.9 Thousand USD | 71.467% |
Alpha Teknova, Inc. | 13.25 Million USD | 99.343% |
Intra-Cellular Therapies, Inc. | 13.32 Million USD | 99.347% |
Bright Green Corporation | 201.78 Thousand USD | 56.884% |
Procaps Group, S.A. | 28.41 Million USD | 99.694% |
Theratechnologies Inc. | 51.26 Million USD | 99.83% |
Harrow Health, Inc. | 183.17 Million USD | 99.953% |
Biofrontera Inc. | 804 Thousand USD | 89.179% |
DURECT Corporation | 2.7 Million USD | 96.78% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 99.738% |
Cronos Group Inc. | 1.55 Million USD | 94.419% |
OptiNose, Inc. | 611 Thousand USD | 85.761% |
Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.983% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.746% |
RedHill Biopharma Ltd. | 455 Thousand USD | 80.879% |
Organogenesis Holdings Inc. | 60.74 Million USD | 99.857% |
Guardion Health Sciences, Inc. | - USD | -Infinity% |
Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 99.319% |
Radius Health, Inc. | 339.66 Million USD | 99.974% |
Universe Pharmaceuticals INC | - USD | -Infinity% |
ProPhase Labs, Inc. | 10.25 Million USD | 99.152% |
Phibro Animal Health Corporation | 458.28 Million USD | 99.981% |
Procaps Group S.A. | 28.41 Million USD | 99.694% |
Alvotech | 1.02 Billion USD | 99.992% |
TherapeuticsMD, Inc. | 6.53 Million USD | 98.668% |
Viatris Inc. | 16.18 Billion USD | 99.999% |
Rockwell Medical, Inc. | 8.29 Million USD | 98.951% |
Aytu BioPharma, Inc. | 10.87 Million USD | 99.2% |
SIGA Technologies, Inc. | 335.99 Thousand USD | 74.106% |
Tilray Brands, Inc. | 287.93 Million USD | 99.97% |
Lifecore Biomedical, Inc. | 120.51 Million USD | 99.928% |
Shineco, Inc. | 10.01 Million USD | 99.132% |
PetIQ, Inc. | 437.82 Million USD | 99.98% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Incannex Healthcare Limited | 210 Thousand USD | 58.571% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.966% |
Alimera Sciences, Inc. | 64.48 Million USD | 99.865% |
Silver Spike Investment Corp. | - USD | -Infinity% |
Assertio Holdings, Inc. | 38.51 Million USD | 99.774% |
Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | 35.598% |
Petros Pharmaceuticals, Inc. | 6.85 Million USD | 98.731% |
Clever Leaves Holdings Inc. | 720 Thousand USD | 87.917% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -286.942% |
Avadel Pharmaceuticals plc | 32.75 Million USD | 99.734% |
Hempacco Co., Inc. | 5.93 Million USD | 98.533% |
Talphera, Inc. | - USD | -Infinity% |
Alvotech | 1.02 Billion USD | 99.992% |
Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.845% |
Lantheus Holdings, Inc. | 616.12 Million USD | 99.986% |
Currenc Group, Inc. | 2.5 Million USD | 96.53% |
Kamada Ltd. | 7.43 Million USD | 98.83% |
Indivior PLC | 235.66 Million USD | 99.963% |
Evoke Pharma, Inc. | 5 Million USD | 98.26% |
Flora Growth Corp. | 942 Thousand USD | 90.764% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -286.942% |
Evolus, Inc. | 120.35 Million USD | 99.928% |
HUTCHMED (China) Limited | 48.18 Million USD | 99.819% |
Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.985% |
Akanda Corp. | 2.49 Million USD | 96.516% |